{"filing":{"accession_number":"0001104659-26-105733","cik":"0001814114","ticker":"OBIO","company_name":"Orchestra BioMed Holdings, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"tm2624943d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926105733/tm2624943d1_8k.htm"},"events":[{"id":31878,"run_id":29277,"accession_number":"0001104659-26-105733","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Orchestra BioMed furnished a corporate overview slide presentation describing its product pipeline, clinical evidence, partnership model, and strategic capital backing from partners including Medtronic and Terumo. The presentation highlights two pivotal-stage programs (AVIM Therapy and Virtue SAB), clinical trial progress, and upcoming catalysts including potential FDA approval and trial enrollment completion, with capital runway disclosed through 2027.","company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34906,"accession_number":"0001104659-26-105733","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate overview slide presentation used at investor and industry conferences. The presentation describes the company's product pipeline, clinical evidence, partnership model, and strategic capital from partners like Medtronic and Terumo. While the content discusses material business developments (pivotal trials, FDA Breakthrough Designations, partnership arrangements), the filing itself is a routine disclosure of presentation materials under Regulation FD—a standard practice for investor relations. The substantive events (partnerships, trial progress) have likely been disclosed separately; this is supplemental investor communication material rather than a new material event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:31:42.858063+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34906,"accession_number":"0001104659-26-105733","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate overview slide presentation used at investor and industry conferences. The presentation describes the company's product pipeline, clinical evidence, partnership model, and strategic capital from partners like Medtronic and Terumo. While the content discusses material business developments (pivotal trials, FDA Breakthrough Designations, partnership arrangements), the filing itself is a routine disclosure of presentation materials under Regulation FD—a standard practice for investor relations. The substantive events (partnerships, trial progress) have likely been disclosed separately; this is supplemental investor communication material rather than a new material event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:31:42.858063+00:00","company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","filing_date":"2026-09-08"}]}